Cisplatin suppresses proliferation, migration and invasion of nasopharyngeal carcinoma cells in vitro by repressing the Wnt/β-catenin/Endothelin-1 axis via activating B cell translocation gene 1
Nasopharyngeal carcinoma (NPC) is one of the most commonly diagnosed cancers worldwide with significantly high prevalence in Southern China. Chemoprevention of cancer with alkylating agent compounds could potentially reverse, suppress, or prevent cancer progression. Cisplatin (CIS) is an antineoplastic or cytotoxic platinum-based drug used for chemotherapy of different types of human cancers such as NPC. Nevertheless, the effects of CIS on the migration and invasion of human NPC cells and the underlying molecular mechanisms have not yet been fully scrutinized.
In this work, we tested the effect of CIS on the proliferation, migration and invasion of NPC cells. The results exhibited that this drug exerts remarkable inhibitory effects on the proliferation, migration and invasion of NPC cells in a dose-dependent manner. Western blotting and real time RT-PCR were used for expression analyses.
We found that CIS treatment led to a dose-dependent inhibition of Endothelin-1 (ET1) expression, at protein as well as mRNA levels in NPC cells. CIS was also found to activate the expression of BTG1 in NPC cells. Moreover, mechanistic analyses revealed that CIS increased the expression of B cell translocation gene 1 (BTG1) to suppress the expression of ET1. Furthermore, we show that ET1 could not be induced in CIS-resistant cells with suppressed BTG1 expression, and subsequently demote the proliferation, migration and invasion of NPC cells.
These findings provided compelling evidence of the role of CIS in suppressing NPC metastasis and its underlying molecular mechanisms.
KeywordsCisplatin Nasopharyngeal carcinoma Endothelin-1 B cell translocation gene 1
Compliance with ethical standards
Conflict of interest
Author Peng Yin declares that he has no conflict of interest. Author Guizhen Song declares that she has no conflict of interest. Author Zhenhua Jiang declares that she has no conflict of interest.
This article does not contain any studies with human participants or animals performed by any of the authors.
- 1.Cui Q, Feng FT, Xu M, Liu WS, Yao YY, Xie SH, Li XZ, Ye ZL, Feng QS, Chen LZ, Bei JX, Feng L, Huang QH, Jia WH, Cao SM, Chang ET, Ye W, Adami HO, Zeng YX (2016) Nasopharyngeal carcinoma risk prediction via salivary detection of host and Epstein–Barr virus genetic variants. Oncotarget. https://doi.org/10.18632/oncotarget.11144 Google Scholar
- 2.Jin GQ, Yang J, Liu LD, Su DK, Wang DP, Zhao SF, Liao ZL (2016) The diagnostic value of 1.5-T diffusion-weighted MR imaging in detecting 5–10 mm metastatic cervical lymph nodes of nasopharyngeal carcinoma. Medicine 95(32):e4286. https://doi.org/10.1097/md.0000000000004286 CrossRefPubMedPubMedCentralGoogle Scholar
- 3.Lu L, Li J, Zhao C, Xue W, Han F, Tao T, Chang H, Jia W, Lu T (2016) Prognostic efficacy of combining tumor volume with Epstein-Barr virus DNA in patients treated with intensity-modulated radiotherapy for nasopharyngeal carcinoma. Oral Oncol 60:18–24. https://doi.org/10.1016/j.oraloncology.2016.06.013 CrossRefPubMedGoogle Scholar
- 4.Maingon P, Blanchard P, Bidault F, Calmels L (2016) Radiotherapy for nasopharyngeal carcinoma. Cancer radiotherapie: journal de la Societe francaise de radiotherapie oncologique. https://doi.org/10.1016/j.canrad.2016.07.031
- 5.Yao K, Yang S, Shen J, Zhang R, Li L (2016) HLA-DRB1 allele polymorphism and nasopharyngeal carcinoma risk: a meta-analysis. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc (EUFOS) Affil German Soc Oto-Rhino-Laryngol Head Neck Surg. https://doi.org/10.1007/s00405-016-4264-2
- 7.Wang Y, Wang ZQ, Jiang YX, Wang FH, Luo HY, Liang Y, Wang DS, Li YH (2016) A triplet chemotherapy regimen of cisplatin, fluorouracil and paclitaxel for locoregionally recurrent nasopharyngeal carcinoma cases contraindicated for re-irradiation/surgery. Expert Opin Pharmacother 17(12):1585–1590. https://doi.org/10.1080/14656566.2016.1204293 CrossRefPubMedGoogle Scholar
- 9.Group INCS., Trial VI (1996) Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV (≥ N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. Int J Radiat Oncol Biol Phys 35(3):463–469CrossRefGoogle Scholar
- 12.Lin SX, Zhang Y, Lu J, Liu X, Li XP (2016) Silencing of endothelin-1 suppresses growth, migration, and invasion of nasopharyngeal carcinoma cells in vitro. J Southern Med Univ 36(7):915–920Google Scholar
- 21.Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M, Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Can Res 55(21):5038–5042Google Scholar
- 23.Sun X-J, Zhang P, Li H-H, Jiang Z-W, Jiang C-C, Liu H (2013) Cisplatin combined with metformin inhibits migration and invasion of human nasopharyngeal carcinoma cells by regulating E-cadherin and MMP-9. APJCP 15(9):4019–4023Google Scholar
- 24.Li M, Balch C, Montgomery JS, Jeong M, Chung JH, Yan P, Huang TH, Kim S, Nephew KP (2009) Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer. BMC Med Genom 2:34. https://doi.org/10.1186/1755-8794-2-34 CrossRefGoogle Scholar
- 33.Han X, Zhen S, Ye Z, Lu J, Wang L, Li P, Li J, Zheng X, Li H, Chen W, Zhao L, Li X (2017) A feedback loop between miR-30a/c-5p and DNMT1 mediates cisplatin resistance in ovarian cancer cells. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 41 (3):973–986. https://doi.org/10.1159/000460618
- 38.Li P, Yang X, Cheng Y, Zhang X, Yang C, Deng X, Li P, Tao J, Yang H, Wei J, Tang J, Yuan W, Lu Q, Xu X, Gu M (2017) MicroRNA-218 increases the sensitivity of bladder cancer to cisplatin by targeting Glut1. Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol 41(3):921–932. https://doi.org/10.1159/000460505
- 41.Stewart CA, Tong P, Cardnell RJ, Sen T, Li L, Gay CM, Masrorpour F, Fan Y, Bara RO, Feng Y, Ru Y, Fujimoto J, Kundu ST, Post LE, Yu K, Shen Y, Glisson BS, Wistuba I, Heymach JV, Gibbons DL, Wang J, Byers LA (2017) Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. Oncotarget. https://doi.org/10.18632/oncotarget.15338 Google Scholar
- 44.Yu N, Xiong Y, Wang C (2017) Bu-Zhong-Yi-Qi decoction, the water extract of chinese traditional herbal medicine, enhances cisplatin cytotoxicity in A549/DDP cells through induction of apoptosis and autophagy. BioMed Res Int 2017:3692797. https://doi.org/10.1155/2017/3692797 PubMedPubMedCentralGoogle Scholar
- 53.Gao Y, Liu Z, Zhang X, He J, Pan Y, Hao F, Xie L, Li Q, Qiu X, Wang E (2013) Inhibition of cytoplasmic GSK-3beta increases cisplatin resistance through activation of Wnt/beta-catenin signaling in A549/DDP cells. Cancer Lett 336(1):231–239. https://doi.org/10.1016/j.canlet.2013.05.005 CrossRefPubMedGoogle Scholar